The EU Commission prohibits the acquisition of a genetic analysis provider by a cancer detection healthcare company (Illumina / GRAIL)

KEYWORDS
Reference

European Commission, Illumina / GRAIL, Press release, 6 September 2022

On 6 September 2022, the European Commission (the Commission ) prohibited the acquisition of cancer detection test start-up Grail by genetic and genomic analysis firm Illumina (see, attached Commission press releases). This decision formed the dramatic culmination of a procedure which the Commission had started on 19 April 2021 at the request of France, which was later joined by Belgium, Greece, The Netherlands and European Economic Area countries Iceland and Norway (see, Van Bael & Bellis Life Sciences News and Insights of 22 April 2021). The Commission considered to have that ability pursuant to Article 22 of the

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Van Bael & Bellis (Brussels)
    France 37 contributions 20655 visites
  • Van Bael & Bellis (Brussels)
    Royaume-Uni 144 contributions 50250 visites
  • Van Bael & Bellis (Brussels)
    Belgique 46 contributions 23596 visites
  • Van Bael & Bellis (Brussels)
    Belgique 45 contributions 22684 visites

Citation

Michael Clancy, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission prohibits the acquisition of a genetic analysis provider by a cancer detection healthcare company (Illumina / GRAIL), 6 septembre 2022, e-Competitions September 2022, Art. N° 108571

Visites 746

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues